Akeso Announces P-II (COMPASSION-26) Trial Results on Cadonilimab + CT in 1L PDAC

Why It Matters

The results suggest cadonilimab + chemo could become a new standard of care, addressing the historically dismal survival outlook in pancreatic cancer and reshaping first‑line treatment strategies.

Key Takeaways

• Median PFS reached 11.1 months, surpassing historical chemo benchmarks
• Median overall survival exceeded 23 months, a first in 1L PDAC
• Objective response rate 33.9% with disease control rate 96.4%
• Benefit observed in both locally advanced and metastatic cohorts

Pulse Analysis

Pancreatic ductal adenocarcinoma remains one of oncology’s toughest challenges, with five‑year survival under 10 % and limited efficacy from conventional regimens such as FOLFIRINOX or gemcitabine‑nab‑paclitaxel. Immunotherapy has historically struggled in this immunologically cold tumor, but cadonilimab—a bispecific antibody targeting PD‑1 and CTLA‑4—aims to overcome this barrier by simultaneously releasing two checkpoints. The COMPASSION‑26 trial, with more than two years of follow‑up, provides the most compelling efficacy signal for an immuno‑oncology combo in pancreatic cancer to date.

The trial’s median progression‑free survival of 11.1 months and median overall survival beyond 23 months dramatically outpace historical benchmarks, where median OS rarely exceeds 11 months. Moreover, a 12‑month OS rate of 91.7 % and a 24‑month rate of 44.1 % in locally advanced disease suggest durable benefit, while an objective response rate of 33.9 % and disease‑control rate of 96.4 % indicate robust tumor shrinkage and stabilization. These outcomes were consistent across both locally advanced and metastatic cohorts, underscoring the regimen’s broad applicability.

If the data hold in a forthcoming Phase III confirmatory study, cadonilimab could earn accelerated approval, positioning Akeso as a contender against established chemo‑only standards. The potential market impact is sizable, given the $5 billion U.S. pancreatic cancer treatment spend and the unmet need for therapies that extend survival without prohibitive toxicity. Investors will watch closely for regulatory filings, while clinicians may soon have a new tool to shift the therapeutic paradigm for one of the deadliest cancers.